Sidney Kimmel Cancer Center at Jefferson | Strategic Alliance Partners

March 16, 2022

The applications for germline and somatic genetic testing in prostate cancer have skyrocketed, carving out an important role in screening, diagnosis, and treatment.

February 28, 2022

One of the primary goals of the ECOG-ACRIN Health Equity Committee is to continue addressing disparities that limit the representation of minority populations in cancer clinical trials.

January 21, 2022

Edith P. Mitchell, MD, MACP, FCPP, FRCS, shared the inspiration behind the ECOG-ACRIN Health Equity Committee, and discusses ECOG-ACRIN’s efforts in addressing health disparities in cancer care.

January 19, 2022

Edith P. Mitchell, MD, MACP, FCPP, FRCS, shares the inspiration behind the ECOG-ACRIN Health Equity Committee, efforts made to address health disparities, how the pandemic has impacted screening and care in the cancer field, and what needs to be done to get back on track.

January 13, 2022

Leonard G. Gomella, MD, discusses the challenges of optimizing prostate-specific antigen as a biomarker in prostate cancer.

December 20, 2021

Leonard G. Gomella, MD, discusses ongoing studies evaluating novel biomarkers in prostate cancer.

November 22, 2021

Steven J. Cohen, MD, discusses the importance of obtaining an adequate tissue sample for molecular testing in gastrointestinal cancers.

October 26, 2021

Concurrent use of tumor-treating fields, radiation therapy, and temozolomide is under study as a potential treatment for patients with newly diagnosed, stage IV glioblastoma.

October 25, 2021

Wenyin Shi, MD, PhD, discusses the rationale to evaluate a tumor-treating fields therapy in combination with temozolomide and radiation therapy in glioblastoma.

June 01, 2021

Andrew E. Aplin, PhD, has been named Deputy Director for Scientific Strategy of the Sidney Kimmel Cancer Center – Jefferson Health.

March 22, 2021

Atrayee Basu-Mallick, MD, discusses the importance of clinical research examining the role of circulating tumor DNA in patients with colorectal cancer.

March 12, 2021

Daniel Lin, MD, MS, discusses pivotal trials examining important targeted agents for patients with cholangiocarcinoma and the importance of comprehensive genomic testing to guide treatment decisions.

March 11, 2021

Atrayee Basu-Mallick, MD, discusses the emerging role of ctDNA as a predictive biomarker in early-stage CRC and the growing importance of molecular testing in the advanced-stage setting.

March 10, 2021

Atrayee Basu-Mallick, MD, discusses factors to consider when selecting a frontline HER2-directed treatment regimen for patients with colorectal cancer.

March 05, 2021

Atrayee Basu-Mallick, MD, discusses the role of circulating tumor DNA in patients with colorectal cancer.

February 03, 2021

Early detection, personalized treatment approaches, and increased situational awareness have improved cancer patient survival rates. Ongoing dialogue among leading experts can only improve patient outcomes and advance the field of gastrointestinal malignancies.

January 11, 2021

Leonard G. Gomella, MD, discusses the role of genetic testing in prostate cancer.

January 03, 2021

Leonard G. Gomella, MD, discusses the growing importance of genetic testing in prostate cancer.

December 07, 2020

Edith P. Mitchell, MD, FACP, FCPP, FRCP, Associate Director for Diversity Affairs at the Sidney Kimmel Cancer Center – Jefferson Health, has been recognized as a fellow of the Royal College of Physicians of London.

September 14, 2020

In our exclusive interview, Dr. Giri and Dr. Gomella discuss the rationale to create the first multidisciplinary, consensus-driven framework for prostate cancer genetic testing, the importance of having a multidisciplinary team weigh in on the recommendations, and key aspects of the guidelines that could have clinical implications for men in this space.